After months of delay, the U.S. Food and Drug Administration (FDA) has rejected Sanofi‘s application seeking approval of tolebrutinib for the treatment of adults with nonrelapsing secondary progressive multiple sclerosis (MS). While Sanofi announced earlier this month that the decision was likely to be delayed again and that further guidance from the FDA was expected […]
The post FDA denies tolebrutinib approval for nonrelapsing progressive MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com